Capital Research Global Investors Reduces Stake in Endo International PLC (ENDP)
Capital Research Global Investors lowered its position in shares of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 29.8% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,522,588 shares of the company’s stock after selling 4,460,840 shares during the quarter. Capital Research Global Investors owned about 4.71% of Endo International PLC worth $117,537,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently bought and sold shares of ENDP. Russell Investments Group Ltd. raised its stake in Endo International PLC by 13.8% in the first quarter. Russell Investments Group Ltd. now owns 269,453 shares of the company’s stock valued at $3,008,000 after purchasing an additional 32,760 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after purchasing an additional 633,904 shares in the last quarter. Comerica Bank raised its stake in Endo International PLC by 233.7% in the first quarter. Comerica Bank now owns 153,881 shares of the company’s stock valued at $1,736,000 after purchasing an additional 107,761 shares in the last quarter. Karp Capital Management Corp acquired a new position in Endo International PLC in the first quarter valued at about $575,000. Finally, Ameriprise Financial Inc. raised its stake in Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock valued at $6,185,000 after purchasing an additional 483,545 shares in the last quarter. 90.71% of the stock is owned by institutional investors.
Shares of Endo International PLC (ENDP) opened at 8.66 on Friday. The stock’s 50 day moving average price is $8.69 and its 200 day moving average price is $10.62. Endo International PLC has a 12-month low of $7.41 and a 12-month high of $21.87. The company’s market capitalization is $1.93 billion.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Tuesday, August 8th. The company reported $0.93 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.19. The company had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period last year, the firm posted $0.86 EPS. On average, equities research analysts forecast that Endo International PLC will post $3.52 earnings per share for the current year.
In related news, CEO Paul Campanelli purchased 6,500 shares of Endo International PLC stock in a transaction that occurred on Monday, August 14th. The shares were acquired at an average cost of $7.71 per share, for a total transaction of $50,115.00. Following the transaction, the chief executive officer now directly owns 213,620 shares in the company, valued at $1,647,010.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Terrance J. Coughlin purchased 20,000 shares of Endo International PLC stock in a transaction that occurred on Thursday, August 10th. The shares were bought at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the transaction, the chief operating officer now owns 181,369 shares in the company, valued at $1,396,541.30. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 36,000 shares of company stock worth $279,460. 0.50% of the stock is currently owned by insiders.
A number of research firms recently commented on ENDP. ValuEngine raised Endo International PLC from a “hold” rating to a “buy” rating in a research note on Monday. Goldman Sachs Group, Inc. (The) began coverage on Endo International PLC in a research note on Thursday, September 28th. They issued a “sell” rating and a $7.00 price target for the company. Zacks Investment Research raised Endo International PLC from a “strong sell” rating to a “hold” rating in a research note on Monday, September 25th. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $9.00 price target on shares of Endo International PLC in a research note on Sunday, September 17th. Finally, Mizuho reaffirmed a “buy” rating and issued a $14.00 price target (down previously from $19.00) on shares of Endo International PLC in a research note on Tuesday, September 12th. Three analysts have rated the stock with a sell rating, sixteen have given a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $12.80.
Endo International PLC Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.